MiMedx Group (MDXG) to Release Quarterly Earnings on Wednesday

MiMedx Group (NASDAQ:MDXG) is anticipated to release its Q3 2025 results after the market closes on Wednesday, October 29th. Analysts expect MiMedx Group to post earnings of $0.07 per share and revenue of $94.7350 million for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 4:30 PM ET.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Monday, November 13th. The company reported ($0.03) EPS for the quarter. The firm had revenue of $67.69 million during the quarter. MiMedx Group had a net margin of 8.84% and a return on equity of 23.03%. On average, analysts expect MiMedx Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MiMedx Group Price Performance

Shares of NASDAQ:MDXG opened at $6.74 on Wednesday. The company has a 50-day moving average price of $7.02 and a 200 day moving average price of $6.78. MiMedx Group has a 52 week low of $5.59 and a 52 week high of $10.14. The company has a quick ratio of 3.90, a current ratio of 4.39 and a debt-to-equity ratio of 0.08. The company has a market cap of $997.25 million, a P/E ratio of 32.10 and a beta of 1.73.

Institutional Investors Weigh In On MiMedx Group

Hedge funds and other institutional investors have recently modified their holdings of the stock. Headlands Technologies LLC bought a new stake in shares of MiMedx Group in the 2nd quarter worth about $72,000. Osaic Holdings Inc. grew its position in MiMedx Group by 57.2% in the 2nd quarter. Osaic Holdings Inc. now owns 12,943 shares of the company’s stock worth $79,000 after purchasing an additional 4,708 shares during the last quarter. AQR Capital Management LLC grew its position in MiMedx Group by 42.6% in the 1st quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock worth $109,000 after purchasing an additional 4,296 shares during the last quarter. Focus Partners Wealth bought a new position in MiMedx Group in the 1st quarter worth about $128,000. Finally, Tower Research Capital LLC TRC grew its position in MiMedx Group by 116.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 18,162 shares of the company’s stock worth $111,000 after purchasing an additional 9,761 shares during the last quarter. Institutional investors own 79.15% of the company’s stock.

Analysts Set New Price Targets

MDXG has been the subject of a number of research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of MiMedx Group in a research report on Wednesday, October 8th. Cantor Fitzgerald raised their price objective on shares of MiMedx Group from $11.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday, July 31st. Finally, Wall Street Zen raised shares of MiMedx Group from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 2nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, MiMedx Group currently has an average rating of “Moderate Buy” and a consensus price target of $12.00.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.